^
Association details:
| Biomarker: | BIRC3 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EXTENDED FOLLOW-UP IN BIRC3-MUTATED RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX PLUS RITUXIMAB: SUBGROUP ANALYSES OF THE MURANO TRIAL
Published date:
05/14/2020
Excerpt:
Non-silent, deleterious BIRC3 mutations were found in 8/160 (5.0%) pts in the BR arm and 9/153 (5.9%) in the VenR arm....With median follow-up of 48 months, within BR arm, PFS was shorter in BIRC3mut pts (HR=2.2, 95% CI [0.92–5.1], p=0.077, adjusted for TP53, 17pdel and IGHV status, Fig A). In the VenR arm, a reduced PFS benefit for BIRC3mut pts was observed (HR=1.5, 95% CI [0.5–4.3], p=0.44, same adjustments as BR, Fig B)....Similar to the setting of FCR, PFS was reduced in BIRC3mut R/R CLL pts treated with BR, indicating BIRC3 mutation is an independent adverse risk factor with chemoimmunotherapy.
Secondary therapy:
bendamustine
